Method of treating joints with hydrogel implants

Information

  • Patent Grant
  • 8142808
  • Patent Number
    8,142,808
  • Date Filed
    Thursday, May 8, 2008
    16 years ago
  • Date Issued
    Tuesday, March 27, 2012
    12 years ago
Abstract
Implantable biomaterials, particularly hydrogel substrates with porous surfaces, and methods for enhancing the compatibility of biomaterials with living tissue, and for causing physical attachment between biomaterials and living tissues are provided. Also provided are implants suitable for load-bearing surfaces in hard tissue repair, replacement, or augmentation, and to methods of their use. One embodiment of the invention relates to an implantable spinal disc prosthesis.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to the use of surface modified biocompatible materials to promote the attachment of bone or bone-like cells to an implant surface. The surface of the biomaterials, which may include hydrogels, when modified in accordance with the description herein, directs the cells that migrate to the implant site to differentiate into cells that attach and lay down bone or bone-derivative material, or cartilage or cartilaginous material further enhancing the biocompatibility of the implanted device.


2. Background Art


Materials used in the construction of implantable medical devices must be nontoxic, nonantigenic, and noninflammatory. Hydrogels are a preferred type of polymeric material for implantable devices. Because of their high water content, analogous to living tissue, they are superior in biocompatibility to non-hydrous polymeric materials.


U.S. Pat. No. 5,981,826, issued to Ku et al., describes the preparation of polyvinyl alcohol hydrogels (PVA-H) by physically crosslinking an aqueous solution of polyvinyl alcohol (PVA) to produce a gel. The crosslinking is accomplished by subjecting the aqueous PVA solution to multiple cycles of freezing and thawing. One limitation of the prior art is that the hydrogels produced are relatively nonporous and the pore size and degree of porosity, that is the density of the pores within the hydrogel, cannot vary independently of the mechanical properties or stiffness of the hydrogel.


Methods for producing certain porous hydrogels also exist in the art. U.S. Pat. No. 6,268,405 issued to Yao et al., describes methods for creating porous PVA-Hs by including immiscible materials in the polymerization process. After the hydrogel is polymerized, the included immiscible materials are washed out of the hydrogel by an appropriate solvent, yielding pores which are broadly distributed throughout the hydrogel. Controlling the size and density of the pores is accomplished by varying the molecular weight of the immiscible materials. A disadvantage of Yao et al. is that the range of attainable pore sizes is limited. Moreover, the invention of Yao et al. is limited in that it can only produce hydrogels whose pores extend throughout the hydrogel. The pores in Yao et al. are intended to create vascularization of the hydrogel in soft or non-load bearing tissue. A further disadvantage of Yao et al. is that the pore sizes are broadly distributed about the average pore size.


In addition to crosslinking by physical means, hydrogels may be chemically crosslinked using, for example, methods similar to those described by Müller in U.S. Pat. No. 5,789,464. Similarly, chemical crosslinking or polymerization methods may also be used to adhere hydrogels to surfaces, including biological tissues. U.S. Pat. No. 5,900,245, issued to Sawhney et al., describes applications of these techniques. These and other methods for the crosslinking or further polymerization of hydrogels are derived from methods used in the polymer industry and are well known in the art.


Artificial discs intended for the replacement of a damaged intravertebral disc have been described. These are typically articulated devices comprising two rigid metal plates adhered to opposite ends of an elastomeric core. In use, the artificial disc is placed in the intervertebral space and the metal plates are secured to the surfaces of adjacent vertebrae. Various embodiments of artificial discs of this type are described in U.S. Pat. Nos. 5,674,296 and 6,156,067, issued to Bryan et al., U.S. Pat. No. 5,824,094, issued to Serhan et al., U.S. Pat. No. 6,402,785, issued to Zdeblick et al. More recent embodiments, e.g. U.S. Pat. No. 6,419,704, issued to Ferree and U.S. Pat. No. 6,482,234, issued to Weber et al., include descriptions of elastomeric cores that may be formed from materials with different elasticities to better mimic the native structure of spinal discs.


The disadvantages of the artificial disc devices of the prior art are numerous. These prior art devices require the mechanical attachment of rigid artificial materials, such as titanium, directly to the bone with screws, staples, nails, cement, or other mechanical means. These rigid materials are only minimally compatible with natural, living bone and separation of the implant from the bone is often observed over long-term implantation. In addition, materials used in artificial discs of the prior art have physical and mechanical properties distinctly different from those of natural spinal, discs and thus, inadequately duplicate the desired properties of native spinal discs.


Vertebral fusion is still the most commonly performed procedure to treat debilitating pain associated with degenerative spinal disc disease or disc trauma, despite the fact that the procedure has many drawbacks. Vertebral fusion increases stress and strain on the discs adjacent to the fusion site, and it is now widely accepted that fusion is responsible for the accelerated degeneration of adjacent levels. Current multicomponent spinal disc prosthesis designs, elastomeric cores with metal plates on both the upper and lower surfaces, are susceptible to problems with interfacial bonding and wear. These designs have shown spontaneous device detachment due to retraction of bone tissue from the metal surface.


Bone ingrowth and attachment in the art has often required the use of bone promoting growth factors. For example, U.S. Pat. No. 5,108,436, issued to Chu et al., describes using a porous implant for use in load bearing bone replacement which is used in combination with an osteogenic factor such as TGF-β.


Biomedical devices which are implanted in or around bone often fail because of fibrinogen encapsulation of the implant instead of cellular attachment to the implant itself. This encapsulation is a defensive reaction attempting to minimize contact between the body and the implant and is considered a sign of implant incompatibility.


Moreover, the art of bone ingrowth to implantable surface contains a multitude of examples relating to porous directed ingrowth where bone essentially grows into and around channels of the implant. For example, U.S. Pat. No. 4,911,720, issued to Collier et al., discusses the ingrowth of bone into interconnecting pores which essentially locks bone into place. This method is disadvantageous in that bone does not actually attach to the material, instead bone attaches to other bone around the implant. In the unfortunate event that an implant must be removed, this type of Collier ingrowth results in large amounts of disruption to the surrounding bone tissue.


SUMMARY OF THE INVENTION

The present invention describes a biomaterial for implantation into the body. The biomaterial, which can be a hydrogel, possesses a textured surface which is comprised of superficial surface pores. Stated differently, the pores on the surface of the hydrogel substrate do not extend throughout the hydrogel but instead remain within a region near the surface. The hydrogel substrate can be comprised of two or more pore sizes. Specifically, the pores of the first size each have a diameter of between 3 and 1000 micrometers, preferably between 10 and 300 micrometers, and preferably between 30 and 100 micrometers. Further, the pores of the second size would each have a diameter of between 0.5 to 20 micrometers, preferably between 1 to 10 micrometers, and preferably between 2 and 5 micrometers. One embodiment of the present invention provides the second, smaller pores disposed within the first, larger pores. The superficial pores of the present invention extend into the hydrogel substrate less than 1 millimeter, preferably 500 micrometers, and preferably 200 micrometers, from the surface. The hydrogel substrate of the present embodiment can comprise polyvinyl alcohol having a water content of at least 5% and preferably at least 30%.


The present invention is also drawn to a hydrogel substrate comprising a hydrogel surface having thereon a plurality of first substantially uniform superficial pores and a unique plurality of second substantially uniform superficial pores. This hydrogel can possess two different yet substantially uniform superficial pore sizes grouped into a first, larger pore size and a second, smaller pore size. The pores of one size are substantially uniform in diameter relative to the other pores of the same size. Specifically, the first pores have an average diameter of between 2 and 600 micrometers, preferably between 5 and 200 micrometers, and preferably between 20 and 60 micrometers. Further, the second pores have an average diameter of between 0.1 and 10 micrometers, preferably between 0.2 to 5 micrometers, and preferably between 0.5 to 2 micrometers. The superficial pores of the present invention can be arranged so that the smaller, second pores are within the larger, first pores. The superficial pores of the present invention extend into the hydrogel substrate less than 1 millimeter, preferably no more than 500 micrometers, and preferably no more than 200 micrometers. The hydrogel substrate of the present embodiment can be made up of polyvinyl alcohol having a water content of at least 5% and preferably at least 30% w/w of the overall hydrogel.





BRIEF DESCRIPTION OF DRAWINGS


FIG. 1 is a spinal disc replacement device made in accordance with one embodiment of the present invention.



FIG. 2 is an example of a superficial surface pore construct exemplary of one embodiment of the present invention.



FIG. 3 are multiple types of superficial surface pores embodied by the present invention.



FIG. 4 is a graph of cell proliferation seen on the surfaces of FIG. 3.



FIG. 5 is a graph of increased bone or bone-like cell markers resulting from exposure to the surfaces of FIG. 3.



FIG. 6 is an image of a substrate which has been generated in accordance with the present invention. The upper image is a further magnification of the image in the lower portion of FIG. 6.





DETAILED DESCRIPTION OF THE INVENTION

The present invention is drawn to a biomaterial substrate which may comprise a hydrogel surface having thereon a plurality of first substantially uniform superficial pores and a unique plurality of second substantially uniform superficial pores. Specifically, the pores of the first size preferably each have a diameter of between 3 and 1000 micrometers, preferably between 10 and 300 micrometers, and preferably between 30 and 100 micrometers, including without limitation, pores with a cross-section of 30, 40, 50, 60, 70, 80, 90, and 100 micrometers. Further, the pores of the second size preferably each have a diameter of between 0.5 to 20 micrometers, preferably between 1 to 10 micrometers, and preferably between 2 and 5 micrometers, including without limitation, pores with a cross-section of 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 micrometers. It should be readily apparent to one of ordinary skill in the art that the use of the term diameter also would encompass the cross-section of the pore when not a perfect circle. In fact, the term “pore” should not be read to be limited to circular or spherical shapes. Squares, polygons, triangles, octagons, quadrahedrens, or any other geometric or amorphic structure would perform the function for the invention if properly positioned and sized. One embodiment of the present invention provides the second, smaller pores within the first, larger pores. The invention provides that third, fourth, fifth, and greater substantially uniform pore sizes can be on the hydrogel surface. By substantially uniform it is meant that the pore sizes of a particular class (e.g., first, second, etc.) do not vary more than 10%, preferably the pore sizes of a particular class vary less than 5%, 4%, 3%, more preferably less than 2%, and preferably less than 1% or 0.5%.


The superficial pores of the present invention would extend into the hydrogel substrate no more than 1 millimeter, preferably 500 micrometers, and preferably 200 micrometers, from the surface. The hydrogel substrate of the present embodiment can comprise polyvinyl alcohol having a water content of at least 5% and preferably at least 30% w/w of the overall hydrogel.


The present invention is also drawn to a hydrogel substrate comprising a hydrogel surface having thereon a plurality of first substantially uniform superficial pores and a unique plurality of second substantially uniform superficial pores. This hydrogel substrate can possess two different yet substantially uniform superficial pore sizes grouped into a first, larger pore size and a second, smaller pore size. The pores of one size are substantially uniform in diameter relative to the other pores of the same size. Specifically, the first pores have an average diameter of between 2 and 600 micrometers, preferably between 5 and 200 micrometers, and preferably between 20 and 60 micrometers. Further, the second pores have an average diameter of between 0.1 and 10 micrometers, preferably between 0.2 to 5 micrometers, and preferably between 0.5 to 2 micrometers.


The superficial pores of the present invention can be arranged so that the smaller, second pores are within the larger, first pores. The superficial pores of the present invention can extend into the hydrogel substrate preferably no more than 1 millimeter, preferably no more than 500 micrometers, and preferably no more than 200 micrometers. The hydrogel substrate of the present embodiment can be made up of polyvinyl alcohol having a water content of at least 5% and preferably at least 30% w/w of the overall hydrogel.


In one embodiment of the invention, the superficial pores of the substrate described herein can be arranged in a regular repeating fashion. Such a patter or waffle structure can be used in embodiments of varying pore size as well as in embodiments where the smaller superficial pores are within the area of the larger superficial pores.


A method provided by the present invention of making a hydrogel substrate possessing a textured surface required by the present invention comprises using an extremely accurate etching technology to generate a mold, pouring a liquid solution of the hydrogel into the mold, allowing the liquid hydrogel to polymerize and/or crosslink while in the mold, and removing the solid hydrogel substrate from the mold. The extremely accurate etching technology can be MEMS technology or its equivalent. Also, the hydrogel substrate made from this method could be a polyvinyl alcohol hydrogel having a water content of at least 5% and preferably at least 30% w/w of the overall hydrogel.


The present invention also includes a method for making a hydrogel substrate by contacting solid objects with a liquid hydrogel, allowing the hydrogel to polymerize and crosslink while the solid objects are at least partially immersed in the hydrogel, and removing those solid objects from the polymerized and crosslinked hydrogel to form superficial pores therein. The solid objects used to impart the superficial pores may be made of polystyrene beads. Also, the solid objects used to impart the superficial pores may be grit, sand, silicon, silica, and ultra-fine particulate matter. The solid objects used to create the superficial pores can have a diameter of between 3 and 1000 micrometers, preferably between 10 and 300 micrometers, and preferably between 30 and 100 micrometers.


The solid objects used to create the superficial pores of this invention can be removed by use of an organic solvent or other washing means. This hydrogel can be comprised of polyvinyl alcohol possessing a water content of at least 5% w/w of the overall hydrogel.


Accordingly, the present invention is directed to an implantable hydrogel substrate product, a method of making that product, and a method of using that product which substantially improves upon the limitations existing in the art. The invention provides methods of selectively promoting cellular residence and/or differentiation over a surface as described herein. To achieve these and other advantages in accordance with the purpose of the invention, as embodied and broadly described herein, the invention includes a load bearing biocompatible hydrogel for medical implantation that promotes bone attachment. The hydrogel consists of a surface component which has been optimized for implantation. This is accomplished through pores on the surface having a controlled range in distribution of size. The surface pores are superficial and do not extend throughout the hydrogel.


Hydrogels are materials whose state is between that of a solid and of a liquid. Gels consist of polymeric, i.e. long chain, molecules linked together to form a three-dimensional network and are embedded in a liquid medium. In the case of hydrogels, the liquid medium comprises water. The polymer backbone of hydrogels is formed by hydrophilic monomer units and may be neutral or ionic. Examples of neutral and hydrophilic monomer units are ethylene oxide, vinyl alcohol, (meth)acrylamide, N-alkylated (meth)acrylamides, N-methylol(meth)acrylamide, N-vinylamides, N-vinylformamide, N-vinylacetamide, N-vinyl-N-methylacetamide, N-vinyl-N-methylformamide, hydroxyalkyl (meth)acrylates such as hydroxyethylmethacrylate, vinylpyrrolidone, (meth)acrylic esters of polyethylene glycol monoallyl ethers, allyl ethers, of polyethylene glycols, and sugar units such as glucose or galactose. Examples of cationic hydrophilic monomer units are ethyleneimine (in the protonated form), diallyldimethylammonium chloride and trimethylammonium propylmethacrylamide chloride. Examples of anionic monomer units are (meth)acrylic acid, crotonic acid, maleic acid, fumaric acid, itaconic acid, 2-acrylamido-2-methylpropanesulfonic acid, vinylsulfonic acid, vinylphosphonic acid, 2-methacryloyloxyethanesulfonic acid, 4-vinylbenzenesulfonic acid, allylsulfonic acid, vinyltoluenesulfonic acid and vinylbenzenephosphonic acid.


From the example listing above, a hydrogel for use in the present invention may be selected based upon its biocompatibility and stability at various hydration states. For the purposes of the present invention, a suitable hydrogel will have a moisture content of at least 5% w/w of the overall hydrogel, preferably at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, or 80% w/w of the overall hydrogel.


Initial events following implantation of a biomaterial in an orthotopic surgical site include rapid adsorption of serum constituents onto the implant surface. The first cells that are likely to come into contact with the surface are polymorphonuclear cells, platelets, monocytes, and macrophages. These cells release bioactive factors that promote mesenchymal cell migration to the wound site. In addition to these natural factors associated with wound healing, surgeons frequently use bone graft and bone graft substitutes to improve bone formation. Such materials include osteoinductive agents such as demineralized bone matrix and bone morphogenetic protein. If appropriate signals are present mesenchymal cells with an osteoprogenitor phenotype will continue to differentiate into osteoblasts; of these a subset will become osteocytes. Ultimately, the newly formed bone will be remodeled via osteoclastic resorption. The invention provides that physical stimulation of cells via a controllably textured surface contributes to desired cellular differentiation, adhesion, and acceptance of the implant. The present invention also provides that well-known grafting agents may be incorporated into the hydrogel composition, which include, but are not limited to growth factors, angiogenic agents, antibiotics, and the like.


Chemically modified or polar surfaces are generally known to be able to produce more reactive protein adsorption to the implant surface than unmodified or non-polar surfaces. The increased reactivity of the proteins adsorbed onto the polar surface is thought to promote cellular adhesion to that surface. Therefore, the invention provides that the hydrogel composition can possess chemically modified or polar surfaces.


In general, many materials are well-tolerated in bone, but the success of long-term or chronic implantation often depends on the intimacy of the interface between the material surface and the bone. Microarchitecture of the surface is an important determinant of cell response. It has been observed that osteoblast phenotypic expression is surface-dependent. As described herein, specific surface characteristics enhance osteoblast differentiation while permitting proliferation, leading to optimal cell response to the implantation. Likewise, cartilage or cartilage-derivative cells show enhanced differentiation based on surface microarchitecture. Since both bone and cartilage cells are derived from mesenchymal stem cells and have as a common ancestor, osteoprogenitor cells, the present invention refers to bone and bone-like cells to encompass that branch of the differentiation pathway. Stated differently, the present invention provides for the differentiation of bone cells (for example osteocytes, osteoblasts, osteoclasts) as well as bone-like cells (for example chondrocytes or related cartilaginous tissue producing cells).


The mechanical properties of the material must be appropriate for the application. When the mechanical properties of the material are similar to the mechanical properties of the tissue adjacent to the implant, tissue tolerance of the artificial material is enhanced. Polymeric and elastomeric biomaterials can be fabricated with a wide range of mechanical properties, making them suitable for many applications as implantable devices. Because of their high water content, similar to that of living tissue, hydrogels are superior in biocompatibility to non-hydrous polymeric materials. Polyvinyl alcohol (PVA) is an example of a polymer that can be used to form hydrogels, and has been studied extensively for its potential in biomedical applications. Polyvinyl alcohol hydrogels (PVA-Hs) are biologically well tolerated and compatible with living cartilage tissue.


PVA-Hs can be produced from solution via repeated freezing and thawing cycles that increase the order of the microcrystalline regions, changing the dissolution properties, mesh size, and diffusion properties of the polymer. Also, PVA-Hs can be produced from solution via a slow and sustained transition through the freezing point of the solution. The mechanical properties of PVA-Hs can be varied over a wide range, and stable PVA gels can easily be produced to have an elastic modulus ranging from a few MPa, such as articular cartilage, to about 50 MPa, such as the stiffest portion of the annulus of spinal discs. Increasing the stiffness of a hydrogel can also be achieved through chemical crosslinking. Examples of chemical crosslinker groups are vinyl groups, allyl groups, cinnamates, acrylates, diacrylates, oligoacrylates, methacrylates, dimethacrylates, oligomethacrylates, or other biologically acceptable groups.


Increasing the porosity of a hydrogel substrate produces decreased mechanical strength. When porous hydrogels are used to provide the requisite surface of the present invention, it is advantageous that the porosity not extend throughout the hydrogel, but be limited to a relatively shallow depth below the surface. The thickness of the porous portion of the hydrogel is preferably less than 1 millimeter, less than 500 micrometers, and most preferable less than or equal to 200 micrometers.


The porosity of the hydrogel surface embodied in this invention may be realized in a variety of ways. Molds may be constructed with patterning on the appropriate surfaces of the cavities in the mold. Alternatively, the porosity can be produced by abrasion of a smooth hydrogel surface after molding. Abrading the surface can result in a surface textured such as desired in this invention. Techniques for applying and using abrasives are well known to those of skill in the art.


Using extremely accurate surface building or etching techniques, one can generate extremely intricate surfaces to use as a mold for a surface envisioned by the present invention. Solid free-form fabrication methods offer several unique opportunities for the construction of medical devices. Solid free-form fabrication methods can be used to selectively control composition within the build plane by varying the composition of printed material. This means that unconventional microstructures, such as those with complicated porous networks or unusual gradients, can be designed at a computer-aided design (CAD) terminal and built through a solid free-form process such as three-dimensional printing or MEMS micro-fabrication techniques.


In one embodiment of this invention the molds for casting the hydrogels are created using MEMS micro-fabrication techniques to produce materials with precise repetitive arrays. The microfabrication process uses commercially available, epoxy-based photoresist and standard photolithography masks and techniques to produce the specified surface architecture. The dimensions of features in the x-y plane of the surface are specified by the photomask. The height of the features is dictated by the thickness of the photoresist layer prior to exposure and development. Multiple photoresist layers may be cast and exposed with different masks to build up very complex structures. An example of one such complex feature, with a pseudofractal architecture is shown in the “snowflake” pattern, seen in FIG. 2.


Photolithography is the process of transferring geometric shapes on a mask to the surface of a silicon wafer. The steps involved in the photolithographic process are wafer cleaning; barrier layer formation; photoresist application; soft baking; mask alignment; exposure and development; and hard-baking.


There are two types of photoresist: positive and negative. For positive resists, the resist is exposed with UV light wherever the underlying material is to be removed. In these resists, exposure to the UV light changes the chemical structure of the resist so that it becomes more soluble in the developer. The exposed resist is then washed away by the developer solution, leaving windows of the bare underlying material. The mask, therefore, contains an exact copy of the pattern which is to remain on the wafer.


Negative resists behave in just the opposite manner. Exposure to the UV light causes the negative resist to become polymerized, and more difficult to dissolve. Therefore, the negative resist remains on the surface wherever it is exposed, and the developer solution removes only the unexposed portions. Masks used for negative photoresists, therefore, contain the inverse (or photographic “negative”) of the pattern to be transferred.


MEMS fabrication of hydrogel mold surfaces for use in this invention may, for example, involve standard photolithography techniques and epoxy-based photoresists (SU-8 2000 series, MicroChem, Newton, Mass.) in a Class 10 cleanroom facility. Photolithography masks can be designed, for example, using a CAD program, or its equivalent, and supplied to order (DuPont Photomasks, Inc., Round Rock, Tex.).


One embodiment of this invention is an artificial intevertebral disc, comprising one or more hydrogels shaped substantially similarly to a natural intevertebral disc. The upper and lower surfaces of the hydrogel, or assembly of hydrogels, are constructed to have a textured surface with a defined level of porosity. That porosity depends primarily upon the size and number of the surface features of the mold used to create the surface texture.


Another embodiment of this invention is a substrate used to repair tissue that has been damaged either chronically or acutely. This substrate can be implanted at a damaged area such as knee cartilage, shoulder bursa repair, or other damaged area one skilled in the art would forsee.



FIG. 1 shows a spinal disc replacement envisioned by the present invention. The spinal disc has an upper portion 1 and a lower portion 2. It is the surfaces of the upper portion 1 and lower portion 2 which possess the textured surface envisioned by the present invention. The upper portion 1 and lower portion 2 will be less elastic and more rigid than the inner region 4 which seeks to mimic the nucleus pulposus. Likewise, the spinal disc may have an intermediate region of elasticity 3 which further aids in the function of the spinal disc. The intermediate region of elasticity 3 may or may not differ from the elasticity of either the inner region 4 or the upper portion 1 or lower portion 2.


The size of the pores comprising the textured surface of the hydrogel can aid in promoting adhesion of one cell type over the other. For example, bone cells can show better attachment and results on textured surfaces where the pores are larger than the pores on a textured surface where cartilage cells attach. The ability to promote bone cells to attach to a given surface as compared to cartilage cells can be considered in the design of an implant. For example, a biomedical implanted device which needs a more rigid attachment to the native bone might require the attachment of bone cells as opposed to cartilage cells, requiring using a surface with larger pores. Likewise, a different implant may need to induce cartilage development on the surface of the implant and would instead use the textured surface composed of overall smaller pores to enable that selection. Other factors such as the age, sex, and pre-existing medical condition of the patient would be considered depending upon the circumstances.


Conversely, the present invention provides for a hydrogel substrate that can be implanted which possesses multiple regions on that substrate capable of promoting the differentiation and attachment of both bone and bone-like cells such as, for example, osteocytes and chondrocytes. Such a surface would, after the migration of mesenchymal stem cells, promote the differentiation of the mesenchymal stem cell into the osteoprogenitor cell and ultimately into bone and cartilage cells on each type's respective region. Stated differently, the present invention provides for a single hydrogel substrate that has both bone cell promoting regions and cartilage, or bone-like cell, promoting regions.


Osteoblasts assume distinct morphologies depending on the architectural features of their substrate. On microrough surfaces, as long as the peak-to-peak distance is less than the length of the cell body, the cell bodies become more cuboidal, and anchor themselves to the surface through long dendritic filopodia. In contrast, on smoother surfaces osteoblasts flatten and spread, resulting in a fibroblastic appearance. The cell morphology correlates with the physiological behavior of the cells. On smooth surfaces, prostaglandin synthesis is low, TGF-β1 levels are low, alkaline phosphatase specific activity is low, and osteocalcin levels are low, whereas proliferation rates are relatively high in comparison with cells cultured on rougher surfaces. That is, a greater number of cells may be present on smooth surfaces, but the cells on textured surfaces show greater tendency to proliferate into bone or bone-like cells.


Responsiveness to the surface also depends upon the state of maturation of the cell in the osteoblast lineage. Examinations of numerous cell lines and primary cell cultures from the multipotent fetal rat calvarial cells to the osteocyte cell line MLO-Y4 have occurred. These experiments indicate that as cells become more mature, the stimulatory effect of the microrough surface on differentiation becomes attenuated. It is, however, only on textured surfaces and only in the presence of bone morphogenic protein-2 (BMP-2), that fetal rat calvarial cells are able to establish three dimensional nodules that form mineral in a physiological relevant manner. The results support in vivo observations that a mineral can affect cells directly on the surface as well as distal to the biomaterial indicating that the extracellular signaling factors released by the cells in direct contact with material are sensed by other cells in the microenvironment, and potentially systematically as well.


The surface texture is created by the distribution of pores which do not continue throughout the hydrogel, or stated differently, are superficially located on the hydrogel substrate. These pores can be broken into at least two size groups: large pores and small pores. The large pores can range in size from 3 to 1000 micrometers in diameter. Preferably, the large pores can range in size from 10 to 300 micrometers in diameter. And preferably, the large pores can range in size from 30 to 100 micrometers in diameter. The small pores are smaller in diameter. For example, the small pores can range in size from 0.5 to 20 micrometers in diameter. Preferably, the small pores can range in size from 1 to 10 micrometers. And preferably, the small pores can range in size from 2 to 5 micrometers. The present invention also provides for third, fourth, fifth, and greater numbers of pore sizes on the hydrogel substrate.



FIG. 2 depicts a superficial pore 20 as envisioned by the present invention. The superficial pore contains a large pore 10 and a small pore 15. The small pores 15 are located within the large pore 10. The small pores 15, in this embodiment, are equally spaced from one another by one diameter and are positioned in a hexagonal layout.


The pores on the textured surface in this embodiment enable the surface to resemble native bone which has undergone osteoclastic resorption. Increasing the porosity of a PVA-H generally reduces the mechanical strength of the implant. When surface textured hydrogels are used to provide the requisite surface texture, it is advantageous for the pores not to extend throughout the hydrogel, but instead be limited to a relatively shallow depth below the textured surface. The thickness of the porous portion of the hydrogel is less than 1 millimeter, preferably less than 500 micrometers, and preferably less than or equal to about 200 micrometers.


In order to measure differentiation of cells into bone or bone-like cells four markers are known in the art. The presence of alkaline-phosphatase, TGF-β1, PGE2, and osteocalcin function as reliable indicators of cellular differentiation into bone or bone-like cells. Specifically, it has been shown that MG63 osteoblasts, NHOst cells, and fetal rat calvarial cells will attach to surfaces and then differentiate into secretory osteoblasts that exhibit increased levels of alkaline phosphatase activity and osteocalcin. As surface microroughness increases, levels of PGE2 in the conditioned medium also increase. PGE2 stimulates osteoclastic activity at high levels, but is required to be present at low levels for osteoblastic activity to occur. It has been previously shown that the elevated prostaglandin levels that are seen in cultures grown on rough microtopographies appear to be required for enhanced osteogenesis since inhibition of prostaglandin production by indomethacin blocks the increase in osteoblast phenotypic expression on these substrates.


TGF-β1 levels are also surface dependent. The amount of TGF-β1 produced by osteoblasts cultured on surfaces is modulated in a surface dependent manner by factors that regulate osteogenesis and subsequent bone resorption. Regulation of TGF-β1 is important to bone formation for a number of reasons. This growth factor stimulates proliferation of mesenchymal cells and enhances the production of extracellular matrix, particularly of type 1 collagen.


Osteocalcin is the most abundant non-collagenous protein in bone, comprising almost 2% of total protein in the human body. It is important in bone metabolism and is used as a clinical marker for bone turnover, but its precise function remains elusive. With no known enzyme activity, osteocalcin's function depends on its structure. That structure reveals a negatively charged protein surface that places five calcium ions in positions complementary to those in hydroxyapatite, the structural mineral component of bone. In addition to binding to hydroxyapatite, osteocalcin functions in cell signaling and the recruitment of osteoclasts and osteoblasts, which have active roles in bone resorption and deposition, respectively.


The hydrogels of the present invention may contain bioactive factors to further stimulate cell growth or differentiation. These factors, for instance attachment peptides, such as RGD containing peptides, and growth factors such as bone morphogenic proteins, insulin-like growth factor, platelet derived growth factor, fibroblast growth factor, cartilage-derived growth factor, transforming growth factor-beta, and parathyroid hormone related peptide, as well as other regulatory chemicals such as statins, prostaglandins, and mineral ions are well known in the art. These factors may be included in the hydrogels of this invention singly or in combination, and they may be included with or without their respective binding proteins.


The hydrogels of the present invention may also contain bone or cartilage forming cells (osteoblasts or chondrocytes) or precursor cells to bone and cartilage forming cells such as mesenchymal stem cells or osteoprogenitor cells. These precursor cells have the capacity to differentiate into bone and/or cartilage forming cells. Cells may be included in the hydrogels of the present invention alone or in combination with bioactive factors to further stimulate cell growth or differentiation.


Natural intervertebral discs have a tough outer fibrocartilaginous ring called the annulus fibrosus and a soft, inner, highly elastic structure called the nucleus pulposus. The artificial discs of the present invention may contain an inner core constructed to mimic the physical and mechanical properties of the natural nucleus pulposus, surrounded by an annular region constructed to mimic the physical and mechanical properties of the natural annulus fibrosus.


In one embodiment, these regions comprise hydrogels whose water content, degree of polymerization, and degree of crosslinking are routinely adjusted to produce the requisite physical and mechanical properties. The hydrogel comprising the inner core has a higher water content and/or a lower degree of polymerization and/or a lower degree of crosslinking to produce a relatively soft and elastic hydrogel. The hydrogel comprising the outer annular region has a lower water content and/or a higher degree of polymerization and/or crosslinking to produce a relatively hard outer hydrogel which mechanically is tough and stiff. The hydrogels comprising the upper and lower surfaces may substantially resemble the hydrogel comprising the annular region in terms of physical and mechanical properties, water content, and degrees of crosslinking and polymerization. The additional requirement, however, for the surfaces to be textured may allow or require a different combination of physical and mechanical properties in these hydrogels compared to the hydrogel comprising the outer annular region.


In yet another embodiment of the present invention, the hydrogel substrate can be a load bearing patch which can be used in the repair of partially or predominately damaged tissue. For example, the hydrogel substrate bearing the textured surface of the present invention can be relatively thin and small in diameter. That hydrogel substrate can then be placed where deteriorated, either acutely or chronically, cartilage was removed.


In yet another embodiment of the present invention, the hydrogel substrate can be assembled outside the body in a malleable form. The malleable form of the hydrogel substrate can then be placed in the intended area, be it a spinal disc replacement, knee cartilage replacement, shoulder bursa repair, or other use one skilled in the art would foresee. Once in the proper position, the malleable hydrogel substrate could be hardened or polymerized via photopolymerization. Radiation curing or photopolymerization (photo-induced free radical polymerization) has become an important and useful technique for applying and curing coatings, inks and adhesives. Radiation-curable compositions typically comprise as essential components one or more radiation-curable monomers and a photoinitiator. The compositions are applied as a coating to various articles and surfaces and the monomers are polymerized to form a film by exposing the coating of the radiation-curable composition to radiation, typically ultraviolet (UV) or electron-beam radiation. Examples of chemical crosslinker groups are vinyl groups, allyl groups, cinnamates, acrylates, diacrylates, oligoacrylates, methacrylates, dimethacrylates, oligomethacrylates, or other biologically acceptable photopolymerizable groups.


In yet another embodiment of the present invention, the biocompatible material used in implantation is selected from the group of polymers, ceramics, metallics, organo-metallics, or other known biocompatible materials. To be used as described herein, the materials need to be castable, formed by the use of molds, in order to have rendered upon the surfaces of the materials the necessary forms embodied in this invention. Castable ceramics would be a preferred selection as the materials are often formed in manners which resembled native bone or bone structures. Likewise, biocompatible metallic components could be fashioned using the various embodiments of this invention such to direct cellular attachment and proliferation at the surface of the implant.


EXAMPLES
Example 1

A simple mold surface pattern in accordance with this invention, for example, is an array of cylinders which are 5 μm in diameter and 5 μm in height. To construct a mold surface with this pattern, a 4-inch diameter silicon wafer is coated with a 5 μm thick layer of SU-8 2005 by spin coating at 3000 rpm for about 30 seconds. The wafer is then placed on a hotplate at 65° C. for about 1 minute and then at 95° C. for about 2 minutes. The wafer is then exposed to UV light through a photomask defining the array of cylinders using, for example, a mask aligner (Karl Suss MA-6). The exposure time is calculated to give an exposure energy of 75 mJ/cm2 at a wavelength of 365 nm. The exposed areas of the photoresist are then crosslinked by heating the wager on a hotplate at 65° C. for about 1 minute and then at 95° C. for about 1 minute. The unexposed areas of the photoresist are then dissolved away by immersing the wafer in solvent (SU-8 Developer, MicroChem, Newton, Mass.) for about 1 minute with continuous gentle agitation. The completed wafer is then rinsed, for example, with isopropyl alcohol and dried in a stream of nitrogen. Profilometry measurements and evaluation by scanning electron microscopy can be used to verify that the desired surface pattern is produced.


Example 2

A more complicated pattern for a hydrogel mold surface, in accordance with the present invention when generated could for example, consist of an array of cylinders 100 μm in diameter and 100 μm in height. Each cylinder is topped with a smaller array of cylinders, 5 μm in diameter, and 5 μm in height. The construction of such a mold requires two layers of photoresist and two separate exposures of those layers. First, a 4-inch diameter silicon wafer is coated with a 100 μm thick layer of SU-8 2050 by spin coating at 1700 rpm for about 30 seconds. The wafer is then placed on a hotplate at 65° C. for about 4 minutes and then at 95° C. for about 1 minute. The wafer is then exposed to UV light through the photomask defining the array of large cylinders, using, for example, a mask aligner (Karl Suss MA-6). The exposure time is calculated to give an exposure energy of 450 mJ/cm2 at a wavelength of 365 nm.


The exposed areas of the photoresist are then cross-linked by heating the wafer on a hotplate at 65° C. for about 1 minute and then at 95° C. for about 9 minutes. Without developing the first layer, the wafer was coated with a 5 μm thick layer of SU-8 2005 by spin coating at 3000 rpm for about 30 seconds. The wafer is then placed on a hotplate at 65° C. for about 1 minute and then at 95° C. for about 2 minutes. The wafer is then exposed to UV light through the photomask defining the array of small cylinders using, for example, a mask aligner (Karl Suss, MA-6). The exposure time is calculated to give an exposure energy of 75 mJ/cm2 at a wavelength of 365 nm. The exposed areas of the photoresist are then crosslinked by heating the wafer on a hotplate at 65° C. for about 1 minute and then at 95° C. for about 1 minute. Finally, the unexposed areas of both photoresist layers are then dissolved away by immersing the wafer in solvent (SU-8 Developer, MicroChem, Newton, Mass.) for about 9 minutes with continuous gentle agitation. The completed wafer is then rinsed with, for example, isopropyl alcohol and dried in a stream of nitrogen. Profilometry measurements and evaluation by scanning electron microscopy can be used to verify that the desired surface pattern has been produced.


Example 3

Under the methods of this invention, enhanced differentiation of cells into bone or bone-like cells is seen. Specifically, experiments were run using the PVA-H of this invention in multiple forms. This description references FIGS. 3-5 for clarity. As shown in FIG. 3 there were seven conformations of the surface topography taught by this invention used in this experiment—one being smooth hydrogel. Specifically, conformation is described using a two number nomenclature system such as PVA-H 10/2. PVA-H 10/2 refers first to the size of the large pore on the surface. As described above, the large pore can exist in a complex structure resembling a snowflake. The number 10 in the first position represents a large pore of 100 μm in diameter. The number in the second position of the nomenclature system refers to the size and arrangement of the small pores superimposed on the large pore surface. The second position numbers of 2, 5, and 10 refer to a diameter of 2 μm, 5 μm, and 10 μm, respectively. The spacing and orientation of the small pores on the large pore surface follows a hexagonal grid with a spacing between the small pores of twice the diameter of the small pores.


Moving clockwise through FIG. 3, surfaces are shown possessing a 100 μm large pore with a 2 μm small pore (10/2) 50, a 100 μm large pore with a 5 μm small pore (10/5) 55, a 100 μm large pore with a 10 μm small pore (10/10) 60, no large pore with 10 μm small pores (0/10) 65, no large pore with 5 μm small pores (0/5) 70, and no large pore with 2 μm small pores (0/2) 75. Not shown is smooth PVA-H which would receive the 0/0 designation in the above described nomenclature.



FIGS. 4 and 5 when taken together indicate that while tissue culture plastic provides for the greatest amount of cellular proliferation, textured PVA-Hs promote increased differentiation into bone or bone-like cells. MG63 cells were cultured in conditioned media on the surfaces. Specifically, the cells cultured on the 10/10 conformation 60 showed the greatest level of secreted osteocalcin. The next highest amount of osteocalcin secretion was seen in the 10/5 conformation 55. This indicates the enhanced ability to generate differentiation into bone or bone-like cells by the mimicking of native osteoclastic resorption sites on PVA-H by the use of the present invention.



FIG. 6 is an image of the surface of a substrate manufactured in accordance with the present invention. The image shows the surface of a hydrogel that was cast in a mold similar to those depicted in FIG. 3. It should be noted that the substrate could have been generated with this pattern out of any of the materials described herein.


Example 4

Solid polystyrene objects having complex shapes may be fabricated from uniform polystyrene beads by chemically attaching beads of different sizes. This is illustrated by the following example.


To a suspension of carboxyl-modified polystyrene beads (20.3 μm+/−0.43 μm diameter, Bangs Laboratories) in 20 mM MES, pH 4.5 is added a 10-fold excess of water-soluble carbodiimide, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride. After 15 minutes at room temperature, the beads are washed twice by centrifugation and suspension in 20 mM HEPES, pH 7.5 and then resuspended in the same buffer. This suspension is added to a stirred suspension of a sufficient amount of amino-modified polystyrene beads (3.10 μm+/−0.06 μm diameter, Bangs Laboratories) to give a 25-fold molar excess of amino groups over carboxyl groups, in the same buffer. After 3 hours at room temperature, the unreacted excess smaller beads are removed. Microscopic examination shows substantially monodisperse particles composed of 20-μm beads having the majority of their surface covered with a single layer of 3-μm beads.


The polystyrene objects of the foregoing example may be used as a template to fabricate a mold for providing the desired porous surface of the hydrogels of the present invention. This may be accomplished by making a metallic replica of a surface comprising a plurality of polystyrene objects using sputtering and/or metal plating techniques and the like, all of which are well known to those skilled in the art. The metallic replica thus produced may be replicated again and reinforced with further metal or other components, again using methods well known to those skilled in the art. The result is a mold suitable for producing the complex surface texture of the hydrogels of the present invention.


Although the invention has been described with reference to a particular preferred embodiment with its constituent parts, features and the like, these are not intended to exhaust all possible arrangements, mechanical and electrical equivalents, or features, and indeed many other modifications and variations will be ascertainable to those of skill in the art.

Claims
  • 1. A method of repairing damaged tissue, comprising: providing a hydrogel having an outer surface and a depth, said hydrogel comprising: a plurality of first substantially uniform cavities along the outer surface of the hydrogel, each of said first cavities extending to a bottom surface of the corresponding first cavity; anda plurality of second substantially uniform cavities located below at least one of the first cavities, each of said second cavities extending from the bottom surface of the corresponding first cavity;wherein said first cavities are only located on the outer surface of the hydrogel and do not extend throughout the depth of said hydrogel;wherein said second cavities do not extend throughout the depth of said hydrogel;wherein the first cavities promote attraction of bone cells; andwherein the second cavities promote anchoring and growth of said bone cells; andimplanting said hydrogel into a patient.
  • 2. The method of claim 1, wherein said hydrogel comprises a load bearing device.
  • 3. The method of claim 1, wherein said hydrogel is a load bearing device configured for implantation into a joint.
  • 4. The method of claim 1, wherein said hydrogel is configured for implantation into a knee, shoulder or spine.
  • 5. The method of claim 1, wherein the hydrogel comprises polyvinyl alcohol.
  • 6. The method of claim 1, wherein said hydrogel has a moisture content of at least 5% w/w of the overall hydrogel.
  • 7. The method of claim 1, wherein said hydrogel has a moisture content of at least 30% w/w of the overall hydrogel.
  • 8. The method of claim 1, wherein the first cavities promote differentiation of a first cell type, and wherein the second cavities promote differentiation of a second cell type.
  • 9. The method of claim 1, further comprising providing within the hydrogel bone and cartilage forming cells or precursor cells to bone and cartilage forming cells.
  • 10. The method of claim 1, wherein the hydrogel comprises one or more of the following cells types: osteoblasts, chondrocytes, mesenchymal stem cells and osteoprogenitor cells.
  • 11. The method of claim 1, wherein said hydrogel comprises bioactive factors to stimulate growth or differentiation of cells.
  • 12. The method of claim 1, wherein the first cavities and the second cavities are within 1 millimeter of the outer surface of the hydrogel.
  • 13. The method of claim 1, wherein the first cavities have an average cross-section of between 10 to 300 micrometers.
  • 14. A method of treating damaged tissue of a target anatomical area, comprising: delivering a hydrogel to a target anatomical area of a patient, the hydrogel having an outer surface and a depth, said hydrogel comprising: a plurality of first cavities located along the exterior surface of the hydrogel, each of said first cavities extending to a bottom surface of said first cavity; anda plurality of second cavities located below at least one of the first cavities, each of said second cavities extending from the bottom surface of the corresponding first cavity;wherein said first cavities are only located on the exterior surface of the hydrogel and do not extend throughout the depth of said hydrogel;wherein said second cavities do not extend throughout the depth of said hydrogel;wherein the hydrogel comprises polyvinyl alcohol; andimplanting said hydrogel into the target anatomical area so that the exterior surface of the hydrogel at least partially contacts at least one of a bone surface and a cartilage surface to which the hydrogel may subsequently attach.
  • 15. The method of claim 14, wherein said hydrogel is load bearing.
  • 16. The method of claim 14, wherein said hydrogel is configured for implantation into a knee, shoulder or spine.
  • 17. The method of claim 14, wherein the first cavities promote attraction of bone cells, and wherein the second cavities promote anchoring and growth of said bone cells.
  • 18. The method of claim 14, wherein the first cavities and the second cavities are within 1 millimeter of the exterior surface of the hydrogel.
  • 19. The method of claim 14, wherein the first cavities have an average cross-section of between 10 to 300 micrometers.
  • 20. The method of claim 14, wherein the first cavities promote differentiation of a first cell type, and wherein the second cavities promote differentiation of a second cell type.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 11/053,410, filed Feb. 7, 2005, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/542,514, filed Feb. 6, 2004, both of which are incorporated by reference herein in their entireties.

US Referenced Citations (390)
Number Name Date Kind
3276996 Lazare Oct 1966 A
3663470 Nishimura et al. May 1972 A
3673612 Merrill et al. Jul 1972 A
3849238 Gould et al. Nov 1974 A
3859421 Hucke Jan 1975 A
4083906 Schindler et al. Apr 1978 A
4205400 Shen et al. Jun 1980 A
4351069 Ballintyn et al. Sep 1982 A
4472542 Nambu Sep 1984 A
4517295 Bracke et al. May 1985 A
4524064 Nambu Jun 1985 A
4609337 Wichterle et al. Sep 1986 A
4663358 Hyon et al. May 1987 A
4664857 Nambu May 1987 A
4693939 Ofstead Sep 1987 A
4731081 Tiffany et al. Mar 1988 A
4734097 Tanabe et al. Mar 1988 A
4753761 Suzuki Jun 1988 A
4759766 Buettner-Janz et al. Jul 1988 A
4772284 Suzuki Sep 1988 A
4784990 Nimrod et al. Nov 1988 A
4787905 Loi Nov 1988 A
4808353 Nambu et al. Feb 1989 A
4828493 Nambu et al. May 1989 A
4851168 Graiver et al. Jul 1989 A
4911720 Collier Mar 1990 A
4916170 Nambu Apr 1990 A
4988761 Ikada et al. Jan 1991 A
4995882 Destouet et al. Feb 1991 A
5047055 Bao et al. Sep 1991 A
5080674 Jacobs et al. Jan 1992 A
5095037 Iwamitsu et al. Mar 1992 A
5106743 Franzblau et al. Apr 1992 A
5106876 Kawamura Apr 1992 A
5108428 Capecchi et al. Apr 1992 A
5108436 Chu et al. Apr 1992 A
5118667 Adams et al. Jun 1992 A
5141973 Kobayashi et al. Aug 1992 A
5171322 Kenny Dec 1992 A
5171574 Kuberasampath et al. Dec 1992 A
5192326 Bao et al. Mar 1993 A
5206023 Hunziker Apr 1993 A
5219360 Georgiade Jun 1993 A
5234456 Silvestrini Aug 1993 A
5244799 Anderson Sep 1993 A
5258023 Reger Nov 1993 A
5258042 Mehta Nov 1993 A
5258043 Stone Nov 1993 A
5260066 Wood et al. Nov 1993 A
5287857 Mann Feb 1994 A
5288503 Wood et al. Feb 1994 A
5290494 Coombes et al. Mar 1994 A
5314477 Marnay May 1994 A
5314478 Oka et al. May 1994 A
5326364 Clift, Jr. et al. Jul 1994 A
5336551 Graiver et al. Aug 1994 A
5336767 Della Valle et al. Aug 1994 A
5343877 Park Sep 1994 A
5344459 Swartz Sep 1994 A
5346935 Suzuki et al. Sep 1994 A
5397572 Coombes et al. Mar 1995 A
5399591 Smith et al. Mar 1995 A
5401269 Buttner-Janz et al. Mar 1995 A
5409904 Hecht et al. Apr 1995 A
5410016 Hubbell et al. Apr 1995 A
5442053 Della Valle et al. Aug 1995 A
5458643 Oka et al. Oct 1995 A
5458645 Bertin Oct 1995 A
5489310 Mikhail Feb 1996 A
5490962 Cima et al. Feb 1996 A
5492697 Boyan et al. Feb 1996 A
5494940 Unger et al. Feb 1996 A
5502082 Unger et al. Mar 1996 A
5512475 Naughton et al. Apr 1996 A
5522898 Bao Jun 1996 A
5534028 Bao et al. Jul 1996 A
5541234 Unger et al. Jul 1996 A
5545229 Parsons et al. Aug 1996 A
5556429 Felt Sep 1996 A
5556431 Buttner-Janz Sep 1996 A
5578217 Unger et al. Nov 1996 A
5626861 Laurencin et al. May 1997 A
5645592 Nicolais et al. Jul 1997 A
5656450 Boyan et al. Aug 1997 A
5658329 Purkait Aug 1997 A
5674241 Bley et al. Oct 1997 A
5674295 Ray et al. Oct 1997 A
5674296 Bryan et al. Oct 1997 A
5688459 Mao et al. Nov 1997 A
5700289 Breitbart et al. Dec 1997 A
5705780 Bao Jan 1998 A
5716416 Lin Feb 1998 A
5750585 Park et al. May 1998 A
5766618 Laurencin et al. Jun 1998 A
5769897 Harle Jun 1998 A
5789464 Muller Aug 1998 A
5795353 Felt Aug 1998 A
5824093 Ray et al. Oct 1998 A
5824094 Serhan et al. Oct 1998 A
5844016 Sawhney et al. Dec 1998 A
5847046 Jiang et al. Dec 1998 A
5855610 Vacanti et al. Jan 1999 A
5863297 Walter et al. Jan 1999 A
5863551 Woerly Jan 1999 A
5876452 Athanasiou et al. Mar 1999 A
5876741 Ron Mar 1999 A
5880216 Tanihara et al. Mar 1999 A
5900245 Sawhney et al. May 1999 A
5916585 Cook et al. Jun 1999 A
5925626 Della Valle et al. Jul 1999 A
5928239 Mirza Jul 1999 A
5935129 McDevitt et al. Aug 1999 A
5944754 Vacanti Aug 1999 A
5947844 Shimosaka et al. Sep 1999 A
5948829 Wallajapet et al. Sep 1999 A
5957787 Hwang Sep 1999 A
5976186 Bao et al. Nov 1999 A
5981826 Ku et al. Nov 1999 A
6001352 Boyan et al. Dec 1999 A
6027744 Vacanti et al. Feb 2000 A
6060534 Ronan et al. May 2000 A
6093205 McLeod et al. Jul 2000 A
6102954 Albrektsson et al. Aug 2000 A
6103255 Levene et al. Aug 2000 A
6132465 Ray et al. Oct 2000 A
6156067 Bryan et al. Dec 2000 A
6171610 Vacanti et al. Jan 2001 B1
6187329 Agrawal et al. Feb 2001 B1
6206927 Fell Mar 2001 B1
6224630 Bao et al. May 2001 B1
6231605 Ku May 2001 B1
6255359 Agrawal et al. Jul 2001 B1
6264695 Stoy Jul 2001 B1
6268405 Yao et al. Jul 2001 B1
6271278 Park et al. Aug 2001 B1
6280475 Bao et al. Aug 2001 B1
6337198 Levene et al. Jan 2002 B1
6340369 Ferree Jan 2002 B1
6341952 Gaylo et al. Jan 2002 B2
6344058 Ferree Feb 2002 B1
6355699 Vyakarnam et al. Mar 2002 B1
6358251 Mirza Mar 2002 B1
6371984 Van Dyke et al. Apr 2002 B1
6376573 White et al. Apr 2002 B1
6379962 Holy et al. Apr 2002 B1
6383519 Sapieszko et al. May 2002 B1
6402784 Wardlaw Jun 2002 B1
6402785 Zdeblick et al. Jun 2002 B1
6419704 Ferree Jul 2002 B1
6428576 Haldimann Aug 2002 B1
6451059 Janas et al. Sep 2002 B1
6472210 Holy et al. Oct 2002 B1
6482234 Weber et al. Nov 2002 B1
6531523 Davankov et al. Mar 2003 B1
6533818 Weber et al. Mar 2003 B1
6534084 Vyakarnam et al. Mar 2003 B1
6558421 Fell et al. May 2003 B1
6602291 Ray et al. Aug 2003 B1
6607558 Kuras Aug 2003 B2
6610094 Husson Aug 2003 B2
6629997 Mansmann Oct 2003 B2
6645248 Casutt Nov 2003 B2
6667049 Janas et al. Dec 2003 B2
6686437 Buchman et al. Feb 2004 B2
6707558 Bennett Mar 2004 B2
6710126 Hirt et al. Mar 2004 B1
6726721 Stoy et al. Apr 2004 B2
6733533 Lozier May 2004 B1
6734000 Chin et al. May 2004 B2
6740118 Eisermann et al. May 2004 B2
6773713 Bonassar et al. Aug 2004 B2
6783546 Zucherman et al. Aug 2004 B2
6800298 Burdick et al. Oct 2004 B1
6802863 Lawson et al. Oct 2004 B2
6827743 Eisermann et al. Dec 2004 B2
6840960 Bubb Jan 2005 B2
6849092 Van Dyke et al. Feb 2005 B2
6855743 Gvozdic Feb 2005 B1
6875232 Nigam Apr 2005 B2
6875386 Ward et al. Apr 2005 B1
6875442 Holy et al. Apr 2005 B2
6878384 Cruise et al. Apr 2005 B2
6881228 Zdeblick et al. Apr 2005 B2
6893463 Fell May 2005 B2
6893466 Trieu May 2005 B2
6923811 Carl et al. Aug 2005 B1
6960617 Omidian et al. Nov 2005 B2
6982298 Calabro et al. Jan 2006 B2
6993406 Cesarano, III et al. Jan 2006 B1
7008635 Coury et al. Mar 2006 B1
7012034 Heide et al. Mar 2006 B2
7022522 Guan et al. Apr 2006 B2
7048766 Ferree May 2006 B2
7052515 Simonson May 2006 B2
7060097 Fraser et al. Jun 2006 B2
7066958 Ferree Jun 2006 B2
7066960 Dickman Jun 2006 B1
7083649 Zucherman et al. Aug 2006 B2
7091191 Laredo et al. Aug 2006 B2
7156877 Lotz et al. Jan 2007 B2
7186419 Petersen Mar 2007 B2
7201774 Ferree Apr 2007 B2
7201776 Ferree et al. Apr 2007 B2
7214245 Marcolongo et al. May 2007 B1
7217294 Kusanagi et al. May 2007 B2
7235592 Muratoglu et al. Jun 2007 B2
7250060 Trieu Jul 2007 B2
7258692 Thelen et al. Aug 2007 B2
7264634 Schmieding Sep 2007 B2
7282165 Williams, III et al. Oct 2007 B2
7291169 Hodorek Nov 2007 B2
7316919 Childs et al. Jan 2008 B2
7332117 Higham et al. Feb 2008 B2
7357798 Sharps et al. Apr 2008 B2
7377942 Berry May 2008 B2
7682540 Boyan et al. Mar 2010 B2
7828853 Ek et al. Nov 2010 B2
7910124 Boyan et al. Mar 2011 B2
8002830 Boyan et al. Aug 2011 B2
20010029399 Ku Oct 2001 A1
20010038831 Park et al. Nov 2001 A1
20010046488 Vandenburgh et al. Nov 2001 A1
20020026244 Trieu Feb 2002 A1
20020031500 MacLaughlin et al. Mar 2002 A1
20020034646 Canham Mar 2002 A1
20020072116 Bhatia et al. Jun 2002 A1
20020140137 Sapieszko et al. Oct 2002 A1
20020173855 Mansmann Nov 2002 A1
20020183845 Mansmann Dec 2002 A1
20020183848 Ray et al. Dec 2002 A1
20020187182 Kramer et al. Dec 2002 A1
20030008395 Holy et al. Jan 2003 A1
20030008396 Ku Jan 2003 A1
20030021823 Landers et al. Jan 2003 A1
20030055505 Sicotte et al. Mar 2003 A1
20030059463 Lahtinen Mar 2003 A1
20030082808 Guan et al. May 2003 A1
20030175656 Livne et al. Sep 2003 A1
20030176922 Lawson et al. Sep 2003 A1
20030199984 Trieu Oct 2003 A1
20030220695 Sevrain Nov 2003 A1
20030233150 Bourne et al. Dec 2003 A1
20040010048 Evans et al. Jan 2004 A1
20040024465 Lambrecht et al. Feb 2004 A1
20040044412 Lambrecht et al. Mar 2004 A1
20040052867 Canham Mar 2004 A1
20040059425 Schmieding Mar 2004 A1
20040063200 Chaikof et al. Apr 2004 A1
20040064195 Herr Apr 2004 A1
20040073312 Eisermann et al. Apr 2004 A1
20040092653 Ruberti et al. May 2004 A1
20040117022 Marnay et al. Jun 2004 A1
20040143327 Ku Jul 2004 A1
20040143329 Ku Jul 2004 A1
20040143333 Bain et al. Jul 2004 A1
20040147016 Rowley et al. Jul 2004 A1
20040171143 Chin et al. Sep 2004 A1
20040172135 Mitchell Sep 2004 A1
20040220296 Lowman et al. Nov 2004 A1
20040220669 Studer Nov 2004 A1
20040220670 Eisermann et al. Nov 2004 A1
20040249465 Ferree Dec 2004 A1
20050037052 Udipi et al. Feb 2005 A1
20050043733 Eisermann et al. Feb 2005 A1
20050043802 Eisermann et al. Feb 2005 A1
20050049706 Brodke et al. Mar 2005 A1
20050055094 Kuslich Mar 2005 A1
20050055099 Ku Mar 2005 A1
20050071003 Ku Mar 2005 A1
20050074877 Mao Apr 2005 A1
20050079200 Rathenow et al. Apr 2005 A1
20050090901 Studer Apr 2005 A1
20050096744 Trieu et al. May 2005 A1
20050106255 Ku May 2005 A1
20050137677 Rush Jun 2005 A1
20050137707 Malek Jun 2005 A1
20050143826 Zucherman et al. Jun 2005 A1
20050149196 Zucherman et al. Jul 2005 A1
20050154462 Zucherman et al. Jul 2005 A1
20050154463 Trieu Jul 2005 A1
20050169963 Van Dyke et al. Aug 2005 A1
20050171608 Peterman et al. Aug 2005 A1
20050177238 Khandkar et al. Aug 2005 A1
20050196452 Boyan et al. Sep 2005 A1
20050209704 Maspero et al. Sep 2005 A1
20050216087 Zucherman et al. Sep 2005 A1
20050228500 Kim et al. Oct 2005 A1
20050233454 Nies et al. Oct 2005 A1
20050244449 Sayer et al. Nov 2005 A1
20050260178 Vandenburgh et al. Nov 2005 A1
20050261682 Ferree Nov 2005 A1
20050273176 Ely et al. Dec 2005 A1
20050273178 Boyan et al. Dec 2005 A1
20050277921 Eisermann et al. Dec 2005 A1
20050278025 Ku et al. Dec 2005 A1
20050287187 Mansmann Dec 2005 A1
20060002890 Hersel et al. Jan 2006 A1
20060052874 Johnson et al. Mar 2006 A1
20060052875 Bernero et al. Mar 2006 A1
20060052878 Schmieding Mar 2006 A1
20060058413 Leistner et al. Mar 2006 A1
20060064172 Trieu Mar 2006 A1
20060064173 Guederian Mar 2006 A1
20060083728 Kusanagi et al. Apr 2006 A1
20060100304 Vresilovic et al. May 2006 A1
20060121609 Yannas et al. Jun 2006 A1
20060122706 Lo Jun 2006 A1
20060136064 Sherman Jun 2006 A1
20060136065 Gontarz et al. Jun 2006 A1
20060200250 Ku Sep 2006 A1
20060206209 Cragg et al. Sep 2006 A1
20060224244 Thomas et al. Oct 2006 A1
20060229721 Ku Oct 2006 A1
20060235541 Hodorek Oct 2006 A1
20060257560 Barone et al. Nov 2006 A1
20060259144 Trieu Nov 2006 A1
20060282165 Pisharodi Dec 2006 A1
20060282166 Molz et al. Dec 2006 A1
20060287730 Segal et al. Dec 2006 A1
20060293561 Abay Dec 2006 A1
20060293751 Lotz et al. Dec 2006 A1
20070010889 Francis Jan 2007 A1
20070014867 Kusanagi et al. Jan 2007 A1
20070032873 Pisharodi Feb 2007 A1
20070038301 Hudgins Feb 2007 A1
20070043441 Pisharodi Feb 2007 A1
20070067036 Hudgins et al. Mar 2007 A1
20070073402 Vresilovic et al. Mar 2007 A1
20070093906 Hudgins et al. Apr 2007 A1
20070106387 Marcolongo et al. May 2007 A1
20070116678 Sung et al. May 2007 A1
20070118218 Hooper May 2007 A1
20070118225 Hestad et al. May 2007 A1
20070134333 Thomas et al. Jun 2007 A1
20070135922 Trieu Jun 2007 A1
20070142326 Shue Jun 2007 A1
20070162135 Segal et al. Jul 2007 A1
20070164464 Ku Jul 2007 A1
20070167541 Ruberti et al. Jul 2007 A1
20070168039 Trieu Jul 2007 A1
20070173951 Wijlaars et al. Jul 2007 A1
20070179606 Huyghe et al. Aug 2007 A1
20070179614 Heinz et al. Aug 2007 A1
20070179615 Heinz et al. Aug 2007 A1
20070179617 Brown et al. Aug 2007 A1
20070179618 Trieu et al. Aug 2007 A1
20070179620 Seaton, Jr. et al. Aug 2007 A1
20070179621 McClellan, III et al. Aug 2007 A1
20070179622 Denoziere et al. Aug 2007 A1
20070196454 Stockman et al. Aug 2007 A1
20070202074 Shalaby Aug 2007 A1
20070203095 Sadozai et al. Aug 2007 A1
20070203580 Yeh Aug 2007 A1
20070208426 Trieu Sep 2007 A1
20070213718 Trieu Sep 2007 A1
20070213822 Trieu Sep 2007 A1
20070213823 Trieu Sep 2007 A1
20070213824 Trieu Sep 2007 A1
20070213825 Thramann Sep 2007 A1
20070224238 Mansmann et al. Sep 2007 A1
20070225823 Hawkins et al. Sep 2007 A1
20070227547 Trieu Oct 2007 A1
20070233259 Muhanna et al. Oct 2007 A1
20070265626 Seme Nov 2007 A1
20070270876 Kuo et al. Nov 2007 A1
20070270970 Trieu Nov 2007 A1
20070270971 Trieu et al. Nov 2007 A1
20070299540 Ku Dec 2007 A1
20080004707 Cragg et al. Jan 2008 A1
20080015697 McLeod et al. Jan 2008 A1
20080021563 Chudzik Jan 2008 A1
20080031962 Boyan et al. Feb 2008 A1
20080045949 Hunt et al. Feb 2008 A1
20080051889 Hodorek Feb 2008 A1
20080057128 Li et al. Mar 2008 A1
20080075657 Abrahams et al. Mar 2008 A1
20080077242 Reo et al. Mar 2008 A1
20080077244 Robinson Mar 2008 A1
20080097606 Cragg et al. Apr 2008 A1
20080103599 Kim et al. May 2008 A1
20080114367 Meyer May 2008 A1
20080125870 Carmichael et al. May 2008 A1
20080131425 Garcia et al. Jun 2008 A1
20080145404 Hill et al. Jun 2008 A1
20080166329 Sung et al. Jul 2008 A1
20080279941 Boyan et al. Nov 2008 A1
20080279943 Boyan et al. Nov 2008 A1
20090182421 Silvestrini et al. Jul 2009 A1
20090263446 Boyan et al. Oct 2009 A1
20110040332 Culbert et al. Feb 2011 A1
Foreign Referenced Citations (58)
Number Date Country
20218703 Mar 2003 DE
0222404 May 1987 EP
0346129 Dec 1989 EP
0505634 Sep 1992 EP
0410010 Oct 1993 EP
0411105 Jun 1995 EP
0845480 Mar 1998 EP
0919209 Jun 1999 EP
1287796 Mar 2003 EP
1030697 Aug 2003 EP
1344538 Sep 2003 EP
1584338 Oct 2005 EP
1482996 Nov 2005 EP
0222407 May 2007 EP
02056882 Mar 1981 GB
02128501 May 1984 GB
02-184580 Jul 1990 JP
04053843 Feb 1992 JP
11035732 Sep 1999 JP
2005-199054 Jul 2005 JP
07247365 Sep 2005 JP
2006-101893 Apr 2006 JP
WO 9007545 Jul 1990 WO
WO 9007575 Jul 1990 WO
WO 9010018 Sep 1990 WO
WO 9316664 Sep 1993 WO
WO 9401483 Jan 1994 WO
WO 9525183 Sep 1995 WO
WO 9706101 Feb 1997 WO
WO 9746178 Dec 1997 WO
WO 9802146 Jan 1998 WO
WO 9850017 Dec 1998 WO
WO 9925391 May 1999 WO
WO 9934845 Jul 1999 WO
WO 0030998 Jun 2000 WO
WO 0042991 Jul 2000 WO
WO 0062829 Oct 2000 WO
WO 0066191 Nov 2000 WO
WO 0102033 Jan 2001 WO
WO 0122902 Apr 2001 WO
WO 0159160 Aug 2001 WO
WO 0164030 Sep 2001 WO
WO 0170436 Sep 2001 WO
WO 0191822 Dec 2001 WO
WO 0209647 Feb 2002 WO
WO 0230480 Apr 2002 WO
WO 02064182 Aug 2002 WO
WO 03030787 Apr 2003 WO
WO 03092760 Nov 2003 WO
WO 2004060554 Jul 2004 WO
WO 2004101013 Nov 2004 WO
WO 2005077304 Aug 2005 WO
WO 2005097006 Oct 2005 WO
WO 2006018531 Feb 2006 WO
WO 2006019634 Feb 2006 WO
WO 2006030054 Mar 2006 WO
WO 2006034365 Mar 2006 WO
WO 2005077013 Aug 2006 WO
Related Publications (1)
Number Date Country
20080279941 A1 Nov 2008 US
Provisional Applications (1)
Number Date Country
60542514 Feb 2004 US
Continuations (1)
Number Date Country
Parent 11053410 Feb 2005 US
Child 12117673 US